Get the Stockscreener App
27.39
4.30%
1.13
Pre-market:
27.00
-0.39
-1.42%
Edgewise Therapeutics Inc stock is traded at $27.39, with a volume of 682.76K.
It is up +4.30% in the last 24 hours and down -11.01% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
See More
Previous Close:
$26.26
Open:
$26.57
24h Volume:
682.76K
Relative Volume:
0.84
Market Cap:
$2.59B
Revenue:
-
Net Income/Loss:
$-115.88M
P/E Ratio:
-17.71
EPS:
-1.5468
Net Cash Flow:
$-104.72M
1W Performance:
-0.47%
1M Performance:
-11.01%
6M Performance:
+28.23%
1Y Performance:
+110.05%
1-Day Range:
$26.00
$27.50
1-Week Range:
$26.00
$30.30
52-Week Range:
$13.10
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
27.39 | 2.59B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Stifel initiates Edgewise Therapeutics stock with Hold rating, $30 target - MSN
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Increases By 8.9% - Defense World
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Rises By 8.9% - MarketBeat
Edgewise Therapeutics Insiders Sold US$1.0m Of Shares Suggesting Hesitancy - Simply Wall St
JPMorgan Chase & Co. Boosts Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 6.1%Time to Sell? - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
December 19th Options Now Available For Edgewise Therapeutics (EWTX) - Nasdaq
How to Take Advantage of moves in (EWTX) - Stock Traders Daily
Edgewise Therapeutics (NASDAQ:EWTX) Trading 7.4% HigherHere's What Happened - MarketBeat
Edgewise Therapeutics Advances Muscular Dystrophy Drug Sevasemten, Nears Pivotal Trial Milestone - StockTitan
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Average Rating of "Buy" by Analysts - MarketBeat
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 - BioSpace
Edgewise CEO to Present Pipeline Updates, 2025 Milestones at J.P. Morgan Healthcare Conference - StockTitan
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownHere's What Happened - MarketBeat
How To Trade (EWTX) - Stock Traders Daily
Edgewise Therapeutics chief scientific officer sells $2.74 million in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Sells $2,737,000.00 in Stock - MarketBeat
Edgewise Therapeutics chief scientific officer sells $2.74 million in stock - Investing.com India
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data (NASDAQ:EWTX) - Seeking Alpha
Franklin Resources Inc. Increases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Franklin Resources Inc. Acquires 20,674 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Marc Semigran Sells 29,709 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock - MarketBeat
Edgewise Therapeutics chief development officer sells $882,914 in stock By Investing.com - Investing.com Canada
Edgewise Therapeutics chief development officer sells $882,914 in stock - Investing.com
(EWTX) Technical Pivots with Risk Controls - Stock Traders Daily
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 2.5%Should You Sell? - MarketBeat
Barclays PLC Increases Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Geode Capital Management LLC Has $42.70 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Bought by Barclays PLC - MarketBeat
Edgewise Therapeutics Inc (NASDAQ: EWTX) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study - MSN
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by State Street Corp - MarketBeat
What is Leerink Partnrs’ Forecast for EWTX FY2026 Earnings? - Defense World
Leerink Partnrs Has Strong Estimate for EWTX FY2026 Earnings - MarketBeat
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Decreases By 10.2% - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Expected to Rise, Evercore ISI Analyst Says - MarketBeat
EWTX Stock Rises On Upbeat Data From Rare Muscular Disorder Study - Barchart
Wellington Management Group LLP Sells 288,526 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease - AOL
Edgewise Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com
Edgewise Therapeutics (NASDAQ:EWTX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
Edgewise weighs fast approval path for muscular dystrophy drug - BioPharma Dive
Edgewise Therapeutics (EWTX) Stock Jumps After Positive Trial News - Stocks Telegraph
Edgewise rises on mid-stage trial results for muscular dystrophy candidate - MSN
Edgewise Therapeutics Shares Higher on Positive Trial Results - MarketWatch
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):